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Background: Circadian variation in renal toxicity of aminoglycosides has been demonstrated in animal and human studies. People with CF are
frequently prescribed aminoglycosides. Altered pharmacokinetics of aminoglycosides are predictive of toxicity.
Aim: To investigate whether the time of day of aminoglycoside administration modulates renal excretion of tobramycin and toxicity in children
with CF. To determine whether circadian rhythms are disrupted in children with CF during hospital admission.
Methods: Children (age 5–18 years) with CF scheduled for tobramycin therapy were randomly allocated to receive tobramycin at 0800 or 2000 h.
Serum tobramycin levels were drawn at 1 h and between 3.5 and 5 h post-infusion between days 5 and 9 of therapy. Melatonin levels were
measured serially at intervals from 1800 h in the evening until 1200 h on the next day. Circadian rhythm was categorised as normal when dim light
melatonin onset was demonstrated between 1800 and 2200 h and/or peak melatonin levels were observed during the night. Weight and spirometry
were measured at the start and end of the therapy. Urinary biomarkers of kidney toxicity (KIM1, NAG, NGAL, IL-18 and CysC) were assayed at
the start and end of the course of tobramycin.
Results: Eighteen children were recruited to the study. There were no differences in renal clearance between the morning and evening groups. The
increase in urinary KIM-1 was greater in the evening dosage group compared to the morning group (mean difference, 0.73 ng/mg; 95% CI, 0.14 to
1.32; p = 0.018). There were no differences in the other urinary biomarkers. There was normal circadian rhythm in 7/11 participants (64%).
Conclusions: Renal elimination of tobramycin was not affected by the time of day of administration. Urinary KIM-1 raises the possibility of greater
nephrotoxicity with evening administration. Four children showed disturbed circadian rhythm and high melatonin levels (ClinicalTrials.gov
NCT01207245).
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Despite recent advances in cystic fibrosis (CF) therapeutics,
the mainstay of treatment of pulmonary exacerbations remains
aggressive antibiotic management. In the UK, registry reportsthor.
ntributed equally to this work.016/j.jcf.2015.07.012
he Authors. Published by Elsevier B.V. on behalf of European
ecommons.org/licenses/by-nc-nd/4.0/).indicate that patients receive a median of 21 days of intravenous
antibiotics per year [1]. Aminoglycosides are commonly
administered in CF, but have been implicated in acute [2,3] and
chronic [4] kidney disease. Patients with CF may have other risk
factors for renal impairment including CF-related diabetes,
concomitant nephrotoxic drugs and immunosuppressive treat-
ment post-transplant.Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
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tobramycin in preference to gentamicin [3] and careful therapeutic
drug monitoring [5]. Extended interval once daily dosing is
less nephrotoxic in cystic fibrosis [6], and has been adopted
as a standard of care in many centres [7]. However, time of day of
administration varies according to unit and patient preference.
Time of day of administration of once daily aminoglyco-
sides could influence toxicity in patients with cystic fibrosis.
In animal models, circadian variation in aminoglycoside
pharmacokinetics and toxicity has been demonstrated [8,9],
although in human subjects, the data are conflicting [10–14].
In a post hoc analysis of a randomised trial of once versus
thrice daily administration of tobramycin in CF (TOPIC)
[15], thrice daily administration was associated with a higher
elimination rate constant (i.e. faster elimination) than the
once daily administration. Once daily dosing was mainly
administered in the evenings. The PK of thrice daily dosing
represented a daily average, indicating that morning elimi-
nation was more rapid. Therefore, we hypothesized that a
once daily dose administered in the morning may be more
rapidly eliminated and hence safer than an evening dose. A
predictable intrinsic circadian variability in elimination of
tobramycin would provide an opportunity for a cost neutral
and easily implementable strategy to reduce the toxicity of
intravenous tobramycin.
We report a randomised pharmacokinetic comparison of once
daily tobramycin in cystic fibrosis, comparing morning with
evening dosing, using a primary pharmacokinetic endpoint. As
one observational study found increased toxicity with evening
administration without a measurable difference in pharmacoki-
netics [11], we evaluated subclinical kidney toxicity with urinary
biomarkers. As an intact circadian rhythm is essential for a
predictable diurnal variability in tobramycin elimination, we
additionally assessed circadian rhythm with melatonin, a robust
marker of circadian rhythm [16].
2. Methods
2.1. Study design and participants
This open label, randomised controlled clinical trial was
conducted in four centres across the Midlands region of the UK
(Nottingham University Hospital NHS Trust, University Hospi-
tals Leicester NHS Trust, Lincoln County Hospital and Pilgrim
Hospital). The study was approved by the regulatory authority
(MHRA) and the National Research Ethics Service (NRES) and
was registered on ClinicalTrials.gov (NCT01207245).
Patients with CF between 5 and 18 years of age were
eligible for inclusion when their treating physician decided to
administer a course of tobramycin. CF was defined as clinical
features of CF in the presence of positive sweat test and/or
presence of two mutations known to be associated with CF.
Study exclusion criteria included history of acute kidney
injury, recipients of solid organ transplant or hypersensitivity
to tobramycin. Patients were recruited from May 2011 until
December 2012. Informed consent and assent were obtained
from the parents/legal guardians and children, respectively.2.2. Drug treatment and pharmacokinetics measurement
All patients received tobramycin and at least a second
intravenous antibiotic which was not pre-specified in the
protocol. The dose of tobramycin was determined as per the
local unit's protocol, which was in line with the CF Trust
Antibiotic Guideline (10 mg/kg/day) [17]. Participants were
randomly assigned to tobramycin administered at either 0800 or
2000 h (infused over 30 min). Randomisation used a remote,
web-based system (Nottingham Clinical Trials Unit), and
randomised participants to each arm in a 1:1 ratio without blocks.
Pharmacokinetic (PK) samples were drawn once in the middle of
the course (day 7 ± 2). Samples were taken at 1 h and between
3.5 and 5 h from the end of the infusion. Samples were analysed
using a homogenous enzyme immunoassay technique (Beckman
Coulter Inc., California, USA). Tobramycin PK parameters were
measured based on a one-compartment model using MwPharm
Version 3.7 (Mediware a.s., Prague, Czech Republic). The PK
parameters determined were elimination rate constant (Kel h
−1),
clearance (CL, L/h), volume of distribution (V, L/kg) and
area-under-the-concentration-time curve (AUC, mg × h/L). Con-
comitant medications were recorded (see Results).
2.3. Urinary biomarkers of nephrotoxicity
Urine samples were collected on day one (prior to treatment)
and at the end of the 14-day treatment course. Samples were
placed on ice immediately, and centrifuged at 4 °C for 15 min
at 1000g, and 1 tablet of protease inhibitor (cOmplete, Mini;
Roche Applied Science) was added to 10 ml of supernatant.
Samples were aliquotted and stored at −80 °C for processing in
batch. The biomarker panel consisted of kidney injury
molecule-1 (KIM1), cystatin C (CysC), neutrophil gelatinase
associated lipocalin (NGAL), interleukin-18 (IL-18) and
N-acetyl-β-D-glucosaminidase (NAG). KIM1, NAG, CysC
and IL-18 were assayed with a sandwich ELISA according to
the manufacturer's instructions (RnD Systems catalogue
numbers DKM100, DLCN20 and DSCTC0, and MBL
International catalogue number 7620). NAG was assayed with
a modification of a kit supplied by Bioquant (catalogue number
BQ062A-EAKP). The data were analysed using the CalibFit
package in R (version 2.15.1). Urinary biomarkers were
normalised to urinary creatinine levels to control for urinary
dilution effects.
2.4. Melatonin measurements and analysis
Saliva samples were collected for melatonin analysis by
passive drooling into collection containers (UltraSal-2™, Oasis
Diagnostics® Corporation, Vancouver, USA). Samples were
collected on day 7 ± 2 at 1800, 1900, 2030, 2130, and 2400 h and
on the next day at 0600 and 1200 h. If a participant was asleep for
an overnight sample, the sample was omitted. The room lights
were dimmed to less than 30 Lx from approximately one hour
before the saliva collection was commenced until waking in the
morning, and participants were advised to take precautions to
prevent contamination with food. Samples visibly contaminated
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radioimmunoassay method (BÜHLMANN direct saliva melato-
nin RIA, Schönenbuch, Switzerland). Dim light melatonin onset
(DLMO) was defined as the time when saliva melatonin levels
increased to ≥4 pg/ml rising from a lower baseline value [18].
For the study purposes, a normal circadian pattern was defined as
either (i) DLMO observed between 1800 and 2200 h, or (ii) a rise
in the melatonin level during the night with a fall in the daytime
[19,20]. Midnight, early morning and midday samples were
collected to identify any abnormal rhythms such as phase reversal
or low melatonin levels. Two investigators independently
categorised the participants as having normal or abnormal
circadian melatonin (APP and KJ) with a third investigator
adjudicating (BK). A sleep quality questionnaire was completed,
including a visual analogue score (from 0 to 10) to describe sleep
quality during one night in the hospital. Visual analogue scores of
7–10, 4–6 and 0–3 were defined as good quality sleep, moderate
quality sleep and poor quality sleep, respectively.
2.5. Other measurements
Serum creatinine levels, weight and height weremeasured at the
beginning of the course. Glomerular filtration rate was estimated
(eGFR) with the Schwartz formula [21]. Weight was measured at
the end of the treatment course. Spirometry was performed by
appropriately trained staff on the ward measuring forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC
at the beginning and end of course of IV treatment according to
ATS/ERS Task Force recommendations [22].
2.6. Outcome measures and statistical analysis
The primary outcome measure of the study was the renal
elimination rate constant for intravenous tobramycin when
given in the morning (0800 h) compared to evening adminis-
tration (2000 h). The secondary outcome measures were (i)
change in biomarker levels over the course of treatment, (ii) the
presence or absence of circadian rhythm in children with CF
and (iii) clinical parameters including the change in weight and
lung function during the course of therapy. We defined the
minimum clinically important difference in Kelr of 30%
between the two groups. We used distribution data from the
TOPIC study (sd of Kelr 0.00035 h
−1/ml/min/1.73 m2) [6] to
inform our power calculation. To achieve a power of 95% to
detect a 30% difference in Kelr, a sample size of 8 patients in
each arm was required (Minitab version 15, Minitab Inc., PA,
USA). We planned for 10 in each arm to allow for a dropout
rate of 20%. Participants who had results available for weight,
height, serum creatinine, tobramycin dose and tobramycin
serum levels including the timing for any one day of the therapy
were included in the primary analysis.
At trial initiation, we planned to employ a one-compartment
Bayesian PK model using estimated glomerular filtration rate
(calculated with the Schwartz formula) within the model priors.
However, data from the CEFIT study (manuscript submitted,
ISRCTN44660887) became available during the conduct of
this study. These results indicate that in the CF population, theSchwartz formula poorly assesses eGFR. In the final analysis
presented herein, we employed a one-compartment model
calculating total body clearance without separating metabolic
(which accounts for around 10%–15% of clearance in
individuals with normal renal function) and renal clearance.
This avoided the need to use an inaccurate calculated eGFR in
the model.
We compared the clearance, elimination rate constant and
half-life between the groups. For biomarker data, we compared
the absolute change (increase) in biomarker levels from the start
to the end of the course of antibiotic for the morning versus the
evening group. Data were tested for normality using QQ plots,
and the Shapiro–Wilk test for normality. Where data were not
normally distributed, deterministic transformations (log, recip-
rocal, square root and powers) were explored. If the data or
suitable transforms of the data were found to be normally
distributed, a Student's T-test was used to compare means. If
the data were not normally distributed, a Wilcoxon test was
used to compare groups. The study results were analysed using
IBM SPSS, Statistics for Windows, version 20 (IBM Corp.,
Armonk, NY, USA) and R version 2.15.2 [23].
3. Results
Twenty-five eligible subjects were identified and approached
(Fig. 1). Consent was given by 18 patients who were randomised
to morning (N = 9) or evening groups (N = 9). Both groups were
similar in characteristics (Table 1) including age, sex, initial
weight, height, serum creatinine and estimated GFR. The second
antibiotic was not pre-specified in the protocol. In most cases, this
was ceftazidime or meropenem (see Table 4). No patient was on a
concomitant nephrotoxic drug (e.g. high dose ibuprofen).
Concomitant medications in each group are given in Table 4.
3.1. Pharmacokinetic results
There was no evidence for a difference in the primary
outcome of pharmacokinetics of the two groups (Table 2). This
finding did not change when a Schwarz formula calculated
eGFR was included in the model (data not shown). Lung
function and weight at the initiation and end of the intravenous
therapy were similar between groups (Table 2).
3.2. Biomarkers of kidney toxicity
Biomarkers (kidney injury molecule-1 (KIM1), cystatin C
(CysC), neutrophil gelatinase associated lipocalin (NGAL),
interleukin-18 (IL-18) and N-acetyl-β-D-glucosaminidase
(NAG)) were assayed. Levels were available for 14 partici-
pants. Four participants dropped out prior to the final day of the
study (three were changed from tobramycin to an alternative
antibiotic prior to the end of the course, and one withdrew
consent). For each biomarker assayed, the increase for each
participant was calculated and the mean difference in the
increase for the morning and evening groups was calculated
(with a log transformation of the data where appropriate)
(Table 3). KIM1 showed a greater rise in the evening compared
Fig. 1. Consort diagram of included participants.
Table 2
Pharmacokinetic and clinical results.
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evening administration (Fig. 2).
3.3. Sleep–wake cycle
A salivarymelatonin profile was obtained for a subgroup of 11
patients. Seven had an intact circadian rhythm, and four had
altered rhythm. Two patients with abnormal rhythm were in the
evening group, and two were in the morning group. The small
number of patients prevented comparisons of pharmacokinetics
and biomarkers in individuals with and without normal circadian
rhythm.
4. Discussion
In a randomised trial comparing dosage time of once daily
tobramycin in CF, we did not find a difference in pharmacoki-
netics between groups administered tobramycin in the morningTable 1
Demographics of enrolled patients.
Characteristics Morning Median
(IQR)
Evening Median
(IQR)
N 9 9
Age (years) 12.5 (12.2–15.5) 14.5 (12.8–14.9)
Weight (Kg) 39.2 (30.4–52.0) 42.0 (38.5–50.7)
Height (cm) 146 (137–165) 164 (162–167)
Serum Creatinine (mmol/L) 57 (40–60) 56 (50–79)
eGFR (ml/min/1.73 m2) 135 (123–165) 121 (100–159)compared to the evening. However, in the pre-specified
secondary endpoint of change in urinary biomarker levels, we
found that urinary KIM1 increased over the treatment course in
participants who received tobramycin in the evening, whereas it
remained approximately static in the morning group. Thus, we
have found some evidence of increased toxicity in evening
administration of tobramycin in the absence of altered pharma-
cokinetics. A significant proportion (4/11) of participants did not
have an intact circadian rhythm.
Ours is the first published randomised study to investigate
circadian variability of pharmacokinetics of tobramycin in
children with cystic fibrosis. Once daily aminoglycoside regimens
have been adopted widely since the publication of the TOPIC
study. In the UK, 90% of paediatric centres and 79% of adult
centres currently use once daily aminoglycosides [7]. TobramycinMorning Evening
n 9 9
Kel (h
−1) 0.41 [0.36 to 0.44] 0.36 [0.34 to 0.46]
Clearance (L/h) 4.1 [3.77 to 4.47] 3.54 [3.39 to 4.51]
T1/2 (h) 1.66 [1.49 to 1.88] 1.89 [1.49 to 2.04]
Vd (l/kg) 0.26 [0.22 to 0.31] 0.24 [0.21 to 0.32]
AUC (h.mg/L) 4.15 [3.09 to 4.85] 3.72 [3.53 to 5.35]
Weight gain (kg) 1.2 [0.7 to 1.5] 0.6 [0.2 to 0.7]
ΔFEV1 (End− Initial) (L) 0.19 [0.07 to 2.20] 0.23 [0.19 to 0.28]
ΔFVC (End− Initial) (L) 0.32 [−0.01 to 0.38] 0.18 [−0.01 to 0.29]
Results are expressed as median [inter-quartile range]. No differences were
found between groups when compared with the Wilcoxon signed rank test.
Table 3
Difference in biomarker increase over the treatment course.
Biomarker Mean change in morning group
(95% CI) a
Mean change in evening group
(95% CI) a
Difference in biomarker increase
(95% CI) b
p-value
KIM1/Cr (ng/mg) 0.01 (−0.43 to 0.46) 0.74 (0.26 to 1.22) 0.73 (0.14 to 1.32) 0.018
CysC/Cr (ng/mg) −16.6 (−51.0 to 17.8) 29.6 (−45.2 to 104.3) 46.2 (−30.7 to 123.0) 0.20 c
NGAL/Cr (ng/mg) 10.1 (−144.7 to 164.9) 12.9 (−76.9 – 102.8) −0.01 (−2.47 to 2.43) d 0.99
IL-18/Cr (pg/mg) −5.72 (−34.3 to 22.9) 139.3 (−221.1 to 499.7) 0.2 (−0.6 to 1.0) d 0.59
NAG/Cr (IU/mg) 0.037 (0.002 to 0.07) 0.052 (−0.001 to 1.034) 0.79 (−0.94 to 2.52) d 0.33
a A positive value indicates that the biomarker level increased over the course of antibiotics.
b A positive difference indicates that the increase in the evening group was greater than the rise in the morning group.
c Indicates p value calculated with Wilcoxon signed rank test (other p values calculated with Student’s T-test).
d Indicates a log transform has been applied to the data (log transformed data shown in this column) before performing the T-test. Urinary biomarker levels were
normalised to urinary creatinine to control for urinary concentration.
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circadian rhythm of glomerular filtration [25]. As toxicity is
increased with greater serum exposure to the drug, more rapid
elimination results in reduced toxicity. The present study was
powered to detect a 30% difference in elimination rate constant
between the two groups. We took samples for pharmacokinetic
analysis between one and three half-lives of tobramycin—the
optimum time to detect differences in elimination rate [28]. WeTable 4
Concomitant medications.
Medication Morning group frequency Evening group frequency
Ceftazidime 8 9
Meropenem 2 2
Co-trimxazole 1 0
Azithromycin 5 8
Beclomethasone 0 1
Calcichew D3 forte 1 1
Cholecalciferol 1 1
Clenil modulite 0 1
Creon 7 8
Dornase alfa 6 9
Doxycycline 0 1
Flixotide 0 1
Flucloxacillin 1 0
Furosemide 0 1
Hypertonic saline 3 2
Insulin 0 1
Itraconazole 1 1
Monteleukast 1 0
Movicol 2 1
Multivitamin 8 5
Nutritional supplement 0 2
Nasonex 1 0
Nystatin 6 5
Omeprazole 5 6
Prednisolone 1 0
Propanolol 0 1
Salbutamol 8 5
Seretide 50 2 1
Sodium picosulphate 0 1
Spironolactone 0 1
Symbicort 0 1
Terbutaline 0 1
Ursodeocycholic acid 3 4
Vitamin A & D 1 2
Vitamin E 6 8
Vitamin K 1 3found no evidence for a difference in pharmacokinetics in
tobramycin administered in the morning compared to the evening.
We report tobramycin clearance as the primary endpoint. At
the trial initiation, we powered for a difference in Kelr (the renal
elimination rate constant). However, we found in the CEFIT
study (ISRCTN44660887, manuscript submitted for publica-
tion) that the Schwartz formula is an unreliable estimator of
glomerular filtration rate. As MwPharm takes into account
estimated GFR when calculating Kelr, we carefully considered
whether Kelr is the correct parameter to report, and concluded
that Kelr has a high chance of bias due to the inaccuracies in
eGFR. We therefore herein report total body tobramycin
clearance, Kel (total body elimination rate constant) and the
half-life, as these do not depend upon eGFR. We also
undertook our original planned analysis of Kelr, and also
found no difference between groups (see online supplement).
The increase in KIM1 (one of our biomarker secondary
endpoints) suggests increased toxicity associated with evening
administration. This result must be viewed with caution, as the
other four biomarkers did not show evidence of a difference
in toxicity. As KIM1 was the only biomarker showing a
difference between groups, and given the multiple testing and
the small sample size, there is a risk of type I error. However,Fig. 2. Increase in urinary KIM1 evening versus morning administration group.
Urinary KIM1 was collected at the start and end of therapy. Lines represent the
mean and standard error of the mean. Levels were normalised to urinary
creatinine to control for urinary concentration (ng KIM1 per mg creatinine).
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the setting of aminoglycoside toxicity. McWilliam found that
KIM1 outperformed NGAL and NAG in neonates exposed to
aminoglycosides [26]. Additionally, KIM1 is elevated after
exposing children with CF to aminoglycoside [27]. From our
results, we do not believe that we can yet recommend that
morning administration is safer than evening administration,
but rather we believe that it is worthwhile to investigate this in a
future study with a larger study size powered specifically for
the KIM1 endpoint.
KIM-1 is an emerging biomarker with evidence of potential
clinical utility accumulating in the literature at a rapid rate.
Urinary KIM1 is a transmembrane protein with extracellular
immunoglobulin and mucin domains [28]. After an acute
nephrotoxic insult to the proximal tubule, urinary levels of
KIM1 increase [29], and KIM1 has been investigated as a
marker of severe acute kidney injury in a variety of settings
[30]. Recently, Shao et al.'s report on the meta-analysis of its
role in acute kidney injury has been published [31]. Within this
meta-analysis, studies found a range of cutoffs for
dichotomising patients into high and low risk of AKI extending
from 0.4 to 2.8 ng/mg. This heterogeneity likely reflects
differences in assays used in the primary studies, different
definitions of AKI, and different populations of patients. Our
results (difference between the increase from baseline when
comparing the morning versus evening group of 0.73 mg) falls
toward the lower end of this range. It is noteworthy that Shao's
meta-analysis found some evidence of publication bias.
We avoided pre-specifying a cutoff for KIM1 at the protocol
phase of our study. Our study was to pilot the biomarker
endpoints to address the relative toxicity of a morning versus
evening group. Data from Al-Aloul et al. [4] indicate that each
course is associated with a small reduction in kidney function
which builds up cumulatively over time. Much of this toxicity
in individual courses is likely to be subclinical and would not
meet the criteria for AKI. Therefore, in our study, we have not
aimed to determine if patients developed AKI, but take the view
that an elevated biomarker level implies greater toxicity (either
subclinical or clinical). Our intention in this present study was
not to determine if a difference between the rates of AKI exists
between the two groups (for which we could measure the
proportion of patients meeting the clinical criteria for AKI), but
to establish if biomarkers support the notion that a morning
dose is less nephrotoxic than the evening group. In this regard,
our study is more akin to that of McWilliam et al. [26], who
studied the profile of KIM1 and other biomarkers in neonates to
determine if they could be used to assess subclinical
nephrotoxicity in patients after exposure to aminoglycosides
in the absence of AKI.
The observation that KIM1 increases with evening but not
morning administration supports the hypothesis that an evening
dose is more toxic than a morning dose. Prins and colleagues
also found increased renal toxicity (as evaluated with a change
in serum creatinine level) with evening administration of
aminoglycosides in the absence of pharmacokinetic differences
[11]. This observational study was performed in adults with
sepsis, and hence other factors could explain the increasedkidney damage in the evening administration group. Within this
context, it remains possible to postulate that increased toxicity
in the evening may occur via a mechanism independent of a
circadian rhythm in pharmacokinetics. An alternate explana-
tion, which incorporates pharmacokinetics, would be that the
evening dose is inherently more nephrotoxic, and has the effect
of gradually prolonging elimination over the two-week course
of antibiotics. This might exacerbate the effect of the evening
dose late in the course of treatment. As we measured
pharmacokinetics midway through the course of tobramycin,
we are unable to exclude this possibility.
We measured salivary melatonin profiles to investigate
circadian rhythm (Fig. 3). This is the first time circadian rhythm
has been investigated in an inpatient CF population with
melatonin. The results were available in 11 (60%) participants.
A normal rhythm was demonstrated in 7/11 children; altered or
no rhythm was observed in 4/11 patients. We have ruled out
participants self-administering melatonin as a potential con-
founder for these results. A limitation of our analysis is that we
assessed sleep–wake cycles once during the admission. To
allow for adjustment to hospital environment, the melatonin
profile was collected in the middle of the course of antibiotics.
We cannot exclude that the sleep–wake cycle changed during
the admission. Indeed, we waited until the middle of the course
to give the rhythm time to entrain to the hospital routine.
However, these results suggest that circadian rhythm is
disrupted in a large proportion of hospitalised patients with
CF. Alternately, other factors may lead to increased melatonin
levels, as it has several roles including antioxidant properties.
There are several limitations to our study. Whilst partici-
pants were randomly allocated to groups, and allocation
concealment was maintained with a web-based randomisation
schedule provided by the Nottingham Clinical Trials Unit, the
two arms of the group were not blinded. There was concern that
blinding would negatively impact upon recruitment by
doubling the number of interventions administered to each
child. We therefore elected to run a non-blinded study. The
small number of participants precluded the assessment of
potential interactions between circadian rhythm and pharma-
cokinetics or biomarkers.
Although the literature describing the role of KIM1 is
steadily increasing, with multiple studies demonstrating its
usefulness as a biomarker of kidney injury in a variety of
settings, the clinical implications of a rise in KIM1 for the
individual patient is not yet known, and requires future work.
The ideal study to address the question of whether morning
versus evening administration is safer would demonstrate a
reduction in a clinically defined AKI endpoint using the
pRIFLE or AKIN criteria. This would require a much larger
sample size. We therefore view the study presented herein as
providing evidence to support a programme of work towards
larger confirmatory studies.
5. Conclusions
This randomised controlled parallel group pharmacokinetic
study found no difference in the renal elimination rate of
Fig. 3. Melatonin profiles. Each plot represents the profile for an individual participant. Purple background (a–g): normal; Yellow Background (h–k): abnormal. For
definitions of normal and abnormal, please see methods.
516 A.P. Prayle et al. / Journal of Cystic Fibrosis 15 (2016) 510–517intravenous tobramycin in those administered it in the morning
versus the evening. In a pre-specified secondary endpoint
biomarker, we found some evidence of reduced toxicity in the
morning group, but this result clearly requires confirmation in afuture larger study. The mechanism of this diurnal nephrotoxicity
independent of tobramycin elimination requires further explora-
tion. Altered circadian rhythm, found by aberrant melatonin levels,
was observed in a large proportion of children with CF.
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